IN2015DN00202A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00202A
IN2015DN00202A IN202DEN2015A IN2015DN00202A IN 2015DN00202 A IN2015DN00202 A IN 2015DN00202A IN 202DEN2015 A IN202DEN2015 A IN 202DEN2015A IN 2015DN00202 A IN2015DN00202 A IN 2015DN00202A
Authority
IN
India
Prior art keywords
mula
inhibitors
compounds
formula
neutrophil elastase
Prior art date
Application number
Other languages
English (en)
Inventor
Carmelida Capaldi
Robert Andrew Heald
Nicholas Charles Ray
Jonathan Mark Sutton
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of IN2015DN00202A publication Critical patent/IN2015DN00202A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN202DEN2015 2012-07-12 2013-07-10 IN2015DN00202A (enEXAMPLES)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12176079 2012-07-12
EP13158756 2013-03-12
PCT/EP2013/064603 WO2014009425A1 (en) 2012-07-12 2013-07-10 Inhibition of enzymes

Publications (1)

Publication Number Publication Date
IN2015DN00202A true IN2015DN00202A (enEXAMPLES) 2015-06-12

Family

ID=48953361

Family Applications (1)

Application Number Title Priority Date Filing Date
IN202DEN2015 IN2015DN00202A (enEXAMPLES) 2012-07-12 2013-07-10

Country Status (10)

Country Link
US (1) US9199984B2 (enEXAMPLES)
EP (1) EP2872509B1 (enEXAMPLES)
KR (1) KR20150031318A (enEXAMPLES)
CN (1) CN104428300B (enEXAMPLES)
AR (1) AR091737A1 (enEXAMPLES)
BR (1) BR112015000507A2 (enEXAMPLES)
CA (1) CA2878792A1 (enEXAMPLES)
IN (1) IN2015DN00202A (enEXAMPLES)
RU (1) RU2638537C2 (enEXAMPLES)
WO (1) WO2014009425A1 (enEXAMPLES)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083626B1 (en) 2013-12-16 2017-10-25 CHIESI FARMACEUTICI S.p.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
US9487528B2 (en) 2014-06-09 2016-11-08 Chiesi Farmaceutici S.P.A. Compounds
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9409870B2 (en) * 2014-12-15 2016-08-09 Chiesi Farmaceutici S.P.A. Compounds
WO2017207432A1 (en) * 2016-05-31 2017-12-07 Chiesi Farmaceutici S.P.A. Novel compounds
MX381423B (es) * 2016-05-31 2025-03-12 Chiesi Farm Spa Compuestos de imidazolona como inhibidores de elastasa de neutrofilo humano.
WO2017207433A1 (en) * 2016-05-31 2017-12-07 Chiesi Farmaceutici S.P.A. Hetetocyclic compounds for use in the treatment of a disease in which hne is implicated
CN120595985A (zh) 2017-02-27 2025-09-05 格扎·巴林特 具有能实现所显示信息和/或数据的同时多功能操作的显示器的智能设备
CA3148216A1 (en) 2019-07-23 2021-01-28 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
AU2020318590A1 (en) 2019-07-23 2022-02-17 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
CA3154761A1 (en) 2019-09-17 2021-03-25 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
BR112022006791A2 (pt) 2019-10-09 2022-06-28 Bayer Ag Novos compostos heteroaril-triazol como pesticidas
BR112022006774A2 (pt) 2019-10-09 2022-06-28 Bayer Ag Compostos de heteroaril-triazol inovadores como pesticidas
US20230117470A1 (en) * 2019-11-01 2023-04-20 Bristol-Myers Squibb Company Substituted pyrazole compounds as toll receptor inhibitors
TW202134226A (zh) 2019-11-18 2021-09-16 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
ES2962498T3 (es) 2020-04-16 2024-03-19 Mereo Biopharma 4 Ltd Métodos que implican el inhibidor de elastasa de neutrófilos alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina
EP4219453A4 (en) * 2020-09-28 2024-10-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. PYRAZOLE COMPOUND AND ITS PREPARATION METHOD AND ITS USE
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
KR20240090272A (ko) 2021-10-20 2024-06-21 메레오 바이오파마 4 리미티드 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259504A (en) 1979-08-27 1981-03-31 American Cyanamid Company Substituted 1H-1,2,4-triazoles
US4451471A (en) 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
US4576958A (en) 1984-01-23 1986-03-18 E. I. Du Pont De Nemours And Company Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
ES2184633B1 (es) 2001-08-07 2004-08-01 J. URIACH & CIA, S.A. Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida.
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
US7902374B2 (en) 2005-05-06 2011-03-08 Universal Display Corporation Stability OLED materials and devices
US20080125587A1 (en) 2006-05-25 2008-05-29 Chimmanamada Dinesh U Synthesis of triazole compounds that modulate HSP90 activity
AR069206A1 (es) * 2007-11-06 2010-01-06 Astrazeneca Ab Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros.
PE20091953A1 (es) 2008-05-08 2010-01-09 Du Pont Azoles sustituidos como fungicidas
US8410128B2 (en) * 2008-06-20 2013-04-02 Bristol-Myers Squibb Company Triazolopyridine compounds useful as kinase inhibitors
JP2011525183A (ja) * 2008-06-20 2011-09-15 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なイミダゾピリジンおよびイミダゾピラジン化合物
DE102009004197A1 (de) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
KR20120099639A (ko) * 2009-10-02 2012-09-11 아스트라제네카 아베 호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물

Also Published As

Publication number Publication date
CA2878792A1 (en) 2014-01-16
EP2872509B1 (en) 2016-09-14
CN104428300B (zh) 2016-11-09
EP2872509A1 (en) 2015-05-20
WO2014009425A1 (en) 2014-01-16
RU2015104644A (ru) 2016-08-27
US9199984B2 (en) 2015-12-01
BR112015000507A2 (pt) 2017-06-27
RU2638537C2 (ru) 2017-12-14
KR20150031318A (ko) 2015-03-23
AR091737A1 (es) 2015-02-25
CN104428300A (zh) 2015-03-18
HK1207078A1 (en) 2016-01-22
US20140018345A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
IN2015DN00202A (enEXAMPLES)
UY34092A (es) Nuevos compuestos como inhibidores de jak
AU2013291345B2 (en) Composition for controlling plant disease and application therefor
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20140024A (es) Compuestos inhibidores de metaloenzimas
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
UY34156A (es) Compuestos inhibidores de metaloenzimas
PH12014502169A1 (en) N-cyclylamides as nematicides
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34654A (es) Inhibidores de la beta-secretasa
UY33958A (es) Inhibidores de la glucosilceramida sintasa
MY164776A (en) Heterocyclic compound
IL228239A0 (en) 3,4-dihydro--pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace)
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
UY33930A (es) Inhibidores novedosos de quinasas
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY34523A (es) Derivados de betulina
IN2015DN01061A (enEXAMPLES)
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
CR20130539A (es) Triazolopiridinas
JO3068B1 (ar) إيميدازوبيريميدينات كمثبطات كيناز akt
IN2014MN01637A (enEXAMPLES)
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
NZ711192A (en) Process for making benzoxazepin compounds